Finally there could be hope for millions of sufferers of Systemic Lupus Erythematosus. Today UK company ImmuPharma announced the last patient had received their last dose in its Phase 3 trial of SLE drug Lupuzor (also known as IPP-201101 or Rigerimod) with the trial due to end in January 2018 and readout shortly afterwards. Results so far have been impressive, with the Phase 2b trial indicating Lupuzor could be more efficaceous, faster acting and lack the side effects of GSK's Benlysta (Benlimumab) together with being available at a lower price. One to watch in the coming weeks and I would love to hear from anyone who took part in any trials. 